I3Y-MC-JPBK: JUNIPER: A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506779-82-00

Acronym

I3Y-MC-JPBK

Enrollment

Registered

2023-10-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

Overall Survival (OS). [ Time Frame: From Randomization Date to Date of Death from Any Cause (Up to 32 Months) ] OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Interventions

DRUGERLOTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS). [ Time Frame: From Randomization Date to Date of Death from Any Cause (Up to 32 Months) ] OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026